Thank you, Mr. Chair, and thank you to all the panellists for being here, especially Dr. Edwards. Thank you for your great efforts, which are definitely helping to lower drug prices.
The positive impact of your recommendation seems clear when it comes to approving and making drugs for new diseases less expensive. How will it be beneficial for developing treatment for well-known and common diseases, like diabetes? That's a big burden on the health care system, to the tune of $27 billion. How can we develop it more efficiently?
Also, I know you said we need a change in the federal policy. Do you think we need more than what is in Motion No. 132, presented by Mr. Saini? Do you think we need to include more policies in it?